COVID-19 Vaccine: Latest Updates
CNBC.com, ” HEALTH AND SCIENCE
Johnson & Johnson reaches deal with U.S. for 100 million doses of coronavirus vaccine at more than $1 billion.”
Milken Institute, Faster Cures Covid-19 Treatment and Vaccine Tracker.
U.S. Health & Human Services Fact Sheet: “Explaining Operation Warp Speed,” June 16, 2020.
News release, AstraZeneca, “COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial,” July 20, 2020 .
The Lancet: “Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase ½, single-blind, randomized controlled trial.”
News release, Pfizer, “Pfizer and BioNTech Choose Lead MRNA Vaccine Candidate,” “Pfizer and BioNTech announce agreement with U.S. government.”
News release, Moderna, “Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins.”
News release, FDA, “Inovio’s Vaccine Candidate Shows Promise in Early Trial.”
News release, Johnson & Johnson, “Johnson & Johnson Announce Acceleration of its COVID-19 Vaccine Candidate; Phase 1-2a Clinical Trial to Begin in Second Half of July.”
News release, Merck: “How We are Responding to the Global Pandemic of COVID-19.”
News release, Novavax: “Novavax Announced Positive Phase 1 Data for its COVID-19 Vaccine Candidate;” “Novavax Announces $1.6 Billion Funding From Operation Warp Speed.”
News release, GlaxoSmithKline: “Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government With 100 Million Doses of COVID-19 Vaccine.”
MD Anderson Center, “COVID-19 herd immunity: 7 questions, answered”
Nature: “Phase 1 / 2 study of COVID-19 RNA vaccine BNT162b1 in adults.”
COVID-19 Prevention Network.
News release, Johnson & Johnson: “Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate.”